Introduction
============

Astaxanthin, a red-orange carotenoid pigment, is a biological antioxidant that naturally found in a wide variety of aquatic living organisms, such as shrimp, crab, and salmon ([@b4-ibpc_1_1]). The green microalgae *Haematococcus pluvialis* and the red yeast *Phaffia rhodozyma* are common sources of natural astaxanthin ([@b4-ibpc_1_1]). Astaxanthin has shown various pharmacological activities, including anti-inflammatory ([@b10-ibpc_1_1]; [@b12-ibpc_1_1]) and antidiabetic activities ([@b16-ibpc_1_1]), as well as antioxidative effects ([@b11-ibpc_1_1]; [@b8-ibpc_1_1]; [@b9-ibpc_1_1]; [@b1-ibpc_1_1]). Here, we discuss an antihypertensive effect of astaxanthin.

Antihypertensive effects of astaxanthin
=======================================

[@b5-ibpc_1_1] investigated an antihypertensive effect of astaxanthin in spontaneously hypertensive rats (SHR), which have been widely used as a model to study the mechanism, pathophysiology, and management of hypertension. The administration of astaxanthin at the doses of 50 mg/kg for 5 weeks demonstrated a significant reduction in the systolic blood pressure (BP) (−4%) and in the diastolic BP (−10%), and also delayed the incidence of stroke in stroke-prone SHR. In the study using aortic rings with intact and denuded endothelia, astaxanthin-induced vasodilation by both endothelium-dependent and endothelium-independent manners. They also investigated the effect of astaxanthin on nitric oxide (NO), which plays a major role on regulation of vascular tone and arterial blood pressure-mediated vasorelaxation. Astaxanthin-mediated vasorelaxation is NO-dependent at the lower dose (30 μM), and is NO-independent at the higher dose (100 μM).

The underlying mechanisms for antihypertensive effects of astaxanthin
=====================================================================

To reveal the underlying mechanisms for antihypertensive effect of astaxanthin, [@b5-ibpc_1_1] evaluated vascular reactivity of the SHR abdominal aorta, induced by various substances that modulate vascular tone and blood pressure. Astaxanthin induced a significant reduction of the contractile responses of the aortic preparations to α-adrenergic receptor agonist, phenylephrine, suggesting that astaxanthin may decrease BP by ameliorating the sympathetic pathway, especially via α-adrenergic receptor. Astaxanthin also demonstrated a significant reduction of the contractile responses to angiotensin II, which has been reported to increase superoxide in cultured vascular smooth muscle cells ([@b3-ibpc_1_1]). Superoxide was increased in rats that became hypertensive by chronic infusion with angiotensin II ([@b13-ibpc_1_1]). These results indicate that astaxan-thin-mediated reduction of the contractile responses of aorta to angiotensin II may be at least partially due to superoxide scavenging effect of astaxanthin.

Astaxanthin has no effect on the endothelium-dependent acetylcholine-induced vasodilation; however, it has a significant enhancing effect in the endothelium-independent sodium nitroprusside (SNP)-induced vasodilation, which challenges previous results. SNP is an endothelium-independent vasorelaxant agent and its effect is attributed to its direct effect on vascular smooth muscles. However, a recent experiment showed that endothelium potentiates the SNP-mediated vasorelaxation, suggesting a significant association between endothelium-mediated vasorelaxation and the SNP-mediated vasorelaxation ([@b2-ibpc_1_1]). Further investigations should be necessary, to elucidate the association between astaxanthin-mediated vasorelaxation and endothelium-mediated vasorelaxation.

[@b7-ibpc_1_1] investigated the effect of astaxanthin on plasma levels of NO end products nitrite/nitrate (NO~2~^−^/NO~3~^−^, termed NOx) in SHR. The synthesis of NO by vascular endothelium is responsible for vascular tone which plays an essential role in regulation of BP ([@b14-ibpc_1_1]). Because NOx are relatively stable in the blood, plasma NOx concentration has been reported to be an indicator of endogenous NO production ([@b15-ibpc_1_1]). Oral administration of astaxanthin significantly reduced plasma NOx levels compared with control rats ([@b7-ibpc_1_1]). We should study the influences of astaxanthin on NO metabolism including degradation and excretion as well as production.

In a histopathological study, astaxanthin decreased coronary artery wall thickness compared with the control, and significantly reduced the elastic fiber in the aorta, suggesting the possibility that astaxanthin ameliorates hypertension-induced vascular remodeling ([@b7-ibpc_1_1]).

Future perspectives
===================

The underlying mechanisms for development of hypertension in the metabolic syndrome, which is characterized by the simultaneous occurrence of metabolic abnormalities including obesity, glucose intolerance, dyslipidemia, are very complicated. Sympathetic overactivity, oxidative stress, and activated renin-anigiotensin system have been suggested to be possible factors for developing hypertension in the metabolic syndrome ([@b17-ibpc_1_1]). Astaxanthin has a superior antioxidant activity, and induces a significant reduction of the contractile responses of the aorta to α-adrenergic receptor agonist and angiotensin II. Astaxanthin may be effective for the management of hypertension in the metabolic syndrome as well as essential hypertension.

Astaxanthin has anti-inflammatory, antidiabetic, antihypertensive, and antioxidative activities; therefore, we should perform further studies to elucidate an antiatherogenic effect of astaxanthin.
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